Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vipul Desai

Infectious Disease The Woodlands, TX Medical Doctor

NPI 1891960969 CMS profile 85624

1111 Medical Plaza Drive, # 170, The Woodlands, TX 77380

Open in the dashboard

General payments

$101,136

1,369 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vipul Desai of The Woodlands, TX is reported in the CMS Open Payments database as having received $101,136 across 1,369 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,823 130
2024 General $13,811 181
2023 General $8,984 206
2022 General $10,243 213
2021 General $14,091 215
2020 General $6,065 152
2019 General $42,118 272

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vipul Desai
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Vipul Desai were reported at $5,823. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Vipul Desai Infectious Disease median Middle half National median
2019 $42,118 $190 $60–$862 $163
2020 $6,065 $124 $32–$606 $114
2021 $14,091 $148 $38–$905 $132
2022 $10,243 $166 $50–$834 $149
2023 $8,984 $171 $57–$787 $160
2024 $13,811 $176 $52–$752 $164
2025 $5,823 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Melinta Therapeutics, Inc. $33,117 107 payments
  2. Cumberland Pharmaceuticals, Inc. $18,135 71 payments
  3. Paratek Pharmaceuticals, Inc. $13,278 95 payments
  4. Ferring Pharmaceuticals Inc. $5,403 16 payments
  5. Gilead Sciences, Inc. $4,563 239 payments
  6. Cipla USA Inc. $4,541 10 payments
  7. Tetraphase Pharmaceuticals, Inc. $4,396 21 payments
  8. Allergan Inc. $2,964 25 payments
  9. ViiV Healthcare Company $2,931 185 payments
  10. AbbVie, Inc. $2,376 113 payments
  11. Other $9,431 487 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $64,100 40 payments
  2. Food and Beverage $29,756 1,285 payments
  3. Honoraria $3,545 2 payments
  4. Travel and Lodging $2,240 18 payments
  5. Education $1,496 24 payments
Products named General payments · program years 2019–2025
  1. Baxdela $31,952 59 payments
  2. VIBATIV Infections and Infectious Diseases $15,883 56 payments
  3. NUZYRA $13,278 95 payments
  4. ZEMDRI (PLAZOMICIN) $4,541 10 payments
  5. Xerava $4,330 18 payments
  6. REBYOTA $3,138 11 payments
  7. AVYCAZ $2,974 23 payments
  8. Vibativ Infections and Infectious Diseases $2,251 15 payments
  9. DALVANCE $1,654 91 payments
  10. Arikayce $1,604 70 payments
  11. Other $15,490 908 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

736

Median for Infectious Disease: 268

Drug cost

$363,975

Median for Infectious Disease: $217,595

Branded share of claims

31%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Arikayce Amikacin Liposomal/Neb.Accessr Brand 12 $180,310
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 25 $105,106
Dovato Dolutegravir Sodium/Lamivudine Brand 12 $34,878
Ertapenem Ertapenem Sodium Brand 32 $15,074
Daptomycin Generic 45 $12,521
Meropenem Generic 34 $3,783
Cefepime Hcl Generic 15 $2,148
Ceftriaxone Ceftriaxone Sodium Brand 15 $1,393
Azithromycin Generic 47 $1,318
Vancomycin Hcl Generic 14 $1,106

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$678,196

Of which drugs: $449,843

Medicare patients

237

Average age 75

Services billed

264,109

129 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 46%
Diabetes 43%
Chronic kidney disease 40%
Heart failure 35%
Atrial fibrillation 33%
COPD 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dalbavancin, 5 mg J0875 Office 49 21,503 $260,771
Injection, omadacycline, 1 mg J0121 Office 23 27,703 $81,868
Injection, daptomycin (xellia), unrefrigerated, not therapeutically equivalent to j0878 or j0873, 1 mg J0872 Office 12 81,188 $15,044
Injection, ertapenem sodium, 500 mg J1335 Office 48 1,063 $9,515
Injection, daptomycin, 1 mg J0878 Office 13 84,600 $4,712
Injection, meropenem, 100 mg J2185 Office 52 7,980 $2,280
Injection, ceftriaxone sodium, per 250 mg J0696 Office 28 2,722 $952

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VIBATIV
$10,304 — —
DALVANCE
$371 — 21,503
CABENUVA
$257 — —
Cresemba
$244 — —
DOVATO
$223 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

1,369 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record